Showing results (221-230 of 305) with videos related to
Sort By:
Pageof 31
European Journal of Clinical Pharmacology|February 7, 2002
The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitroU Yasar, E Eliasson, C Forslund-Bergengren, et al.European Journal of Clinical Pharmacology|February 24, 2001
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patientsM G Scordo, E Spina, P Romeo, et al.Journal of Voice : Official Journal of the Voice Foundation|December 8, 2023
Does Implicit Racial Bias Affect Auditory-Perceptual Evaluations of Dysphonic Voices?Rachel L Norotsky, Kimberly L Dahl, Sarah Cocroft, et al.Journal of Bacteriology|September 26, 2006
CbgA, a protein involved in cortex formation and stress resistance in Myxococcus xanthus sporesFarah K Tengra, John L Dahl, David Dutton, et al.Clinical Pharmacology and Therapeutics|August 1, 1994
Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphismM L Dahl, G Tybring, C E Elwin, et al.Therapeutic Drug Monitoring|August 15, 2000
Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urineJ A Carrillo, M Christensen, S I Ramos, et al.Pharmacogenetics|June 1, 1995
Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjectsM L Dahl, Q Y Yue, H K Roh, et al.British Journal of Clinical Pharmacology|June 20, 2003
Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with CaucasiansP Dalén, M-L Dahl, H-K Roh, et al.Cancer|March 1, 1996
Teaching cancer pain management: durability of educational effects of a role model programN A Janjan, C G Martin, R Payne, et al.Clinical Pharmacology and Therapeutics|November 3, 1998
CYP2D6 polymorphism is not crucial for the disposition of selegilineH Scheinin, M Anttila, M L Dahl, et al.Pageof 31